NGNE NASDAQ
Neurogene Inc.
1W: +6.3%
1M: -5.2%
3M: -19.8%
YTD: +33.9%
1Y: -9.7%
3Y: +105.7%
5Y: -80.8%
$26.99
+3.45 (+14.66%)
Weekly Expected Move ±10.7%
$18
$21
$24
$26
$29
Credit Risk of going bust: lower than 55% of companies Debt: 1.9% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.08 (down 99.7%), Neurogene Inc. would be worth roughly what it owes.
Total debt $8.3M against a stock market value of $426.5M.
Distance to default 5.67 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $4.2M (short-term plus half of long-term), stock volatility 78.0%; Altman Z'' 5.31. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.08 (down 99.7%), Neurogene Inc. would be worth roughly what it owes.
Total debt $8.3M against a stock market value of $426.5M.
Distance to default 5.67 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $4.2M (short-term plus half of long-term), stock volatility 78.0%; Altman Z'' 5.31. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
3 relationships3
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2023-07-18
Earliest Filing
2025-04-14
Latest Filing
partner: 1
target: 1
investor: 1
Counterparties (Filed by NGNE)
3 relationshipsCompanies named in NGNE's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP | — | partner | Amendment to letter agreement regarding director nomination rights threshold | 2025-04-14 | View |
| Neurogene Inc. | NGNE | target | Target company in the merger agreement with Neoleukin Therapeutics, Inc. | 2023-07-18 | View |
| Baker Bros. Advisors LP | — | investor | Investor entering into a letter agreement with Neoleukin Therapeutics, Inc. | 2023-07-18 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-11 | Earnings Release; Exhibits | View | |
| 2026-07-02 | Material Agreement; Other Events; Exhibits | Agreement | View |
| 2026-06-29 | Regulation FD; Other Events; Exhibits | View | |
| 2026-06-08 | Regulation FD; Exhibits | View | |
| 2026-06-04 | Shareholder Vote | View | |
| 2026-05-12 | Earnings Release; Exhibits | View | |
| 2026-04-20 | Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-03-24 | Earnings Release; Exhibits | View | |
| 2026-02-26 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2026-01-12 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-11-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-12 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-11-06 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-10-09 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-08-11 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-30 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-06-12 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2025-06-09 | Other Events; Financial Statements and Exhibits | View | |
| 2025-05-09 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-04-14 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR